Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research Dr. Kavanaugh to Join CytomX Scientific Advisory Board SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company

SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® technology platform, today announced that on

SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody ® therapeutic technology platform, announced

Company to Host a Conference Call Today, August 6, 2020, at 5:30 p.m. ET / 2:30 p.m. PT SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational

SOUTH SAN FRANCISCO, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced

-Teleconference Scheduled for August 6, 2020, at 5:30 p.m. ET- SOUTH SAN FRANCISCO, Calif. , July 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics

Preclinical Data Supports Expanded Therapeutic Index and Provides Rationale for Ongoing Clinical Studies SOUTH SAN FRANCISCO, Calif. , June 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that its partner Bristol Myers Squibb presented preclinical data from

- First Presentation of Clinical Data for CX-2029, a Probody Drug Conjugate,  Directed Against CD71: A Previously Undruggable Target - CX-2029 Waterfall Plot (Doses 2–5 mg/kg) CX-2009 Waterfall Plot and Spider Plot: HER2- Breast Cancer (≥4 mg/kg Every 3 Weeks) CX-072 Monotherapy Waterfall Plots and

SOUTH SAN FRANCISCO, Calif. , May 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody ® therapeutic technology platform, announced

Event Scheduled for Friday, May 29, 2020 at 5:00 p.m. ET / 2:00 p.m. PT SOUTH SAN FRANCISCO, Calif. , May 26, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody